Literature DB >> 6184780

A bean alpha-amylase inhibitor formulation (starch blocker) is ineffective in man.

G L Carlson, B U Li, P Bass, W A Olsen.   

Abstract

A commercial alpha-amylase inhibitor with potent inhibitory activity in vitro was used in a randomized double-blind, cross-over clinical trial in six nonobese, healthy adult males. In these subjects, this inhibitor had no effect on the response of blood glucose, insulin, or breath hydrogen to a standardized starch meal. It is concluded that this formulation has no effect on starch digestion in humans.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6184780     DOI： 10.1126/science.6184780

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


  8 in total

1.  An in vitro and in vivo study of the α-amylase activity of phaseolamin.

Authors:  Neire Moura de Gouveia; Fernanda Vieira Alves; Fabiana Barcelos Furtado; Danielli Luana Scherer; Antonio Vicente Mundim; Foued Salmen Espindola
Journal:  J Med Food       Date:  2014-03-20       Impact factor: 2.786

2.  alpha-amylase inhibitor increases plasma 3-hydroxybutyric acid in food-restricted rats.

Authors:  T Doi; H Yoshimatsu; I Katsuragi; M Kurokawa; H Takahashi; A Motoshio; T Sakata
Journal:  Experientia       Date:  1995-06-14

3.  Bean alpha-amylase inhibitor 1 in transgenic peas (Pisum sativum) provides complete protection from pea weevil (Bruchus pisorum) under field conditions.

Authors:  R L Morton; H E Schroeder; K S Bateman; M J Chrispeels; E Armstrong; T J Higgins
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-11       Impact factor: 11.205

4.  Commercial soybean starch blocker consumption: impact on weight gain and on copper, lead and zinc status of rats.

Authors:  J Umoren; C Kies
Journal:  Plant Foods Hum Nutr       Date:  1992-04       Impact factor: 3.921

5.  The role of lipid and carbohydrate digestive enzyme inhibitors in the management of obesity: a review of current and emerging therapeutic agents.

Authors:  Sonia A Tucci; Emma J Boyland; Jason Cg Halford
Journal:  Diabetes Metab Syndr Obes       Date:  2010-05-10       Impact factor: 3.168

6.  Susceptibility of sweet potato (Ipomoea batatas) peel proteins to digestive enzymes.

Authors:  Katherine P Maloney; Van-Den Truong; Jonathan C Allen
Journal:  Food Sci Nutr       Date:  2014-04-01       Impact factor: 2.863

7.  Heterologous expression of an α-amylase inhibitor from common bean (Phaseolus vulgaris) in Kluyveromyces lactis and Saccharomyces cerevisiae.

Authors:  Stephanie Brain-Isasi; Alejandro Álvarez-Lueje; Thomas Joseph V Higgins
Journal:  Microb Cell Fact       Date:  2017-06-15       Impact factor: 5.328

Review 8.  Common bean (Phaseolus vulgaris L.) α-amylase inhibitors as safe nutraceutical strategy against diabetes and obesity: An update review.

Authors:  Stefania Peddio; Alessandra Padiglia; Faustina B Cannea; Roberto Crnjar; Wissam Zam; Javad Sharifi-Rad; Antonio Rescigno; Paolo Zucca
Journal:  Phytother Res       Date:  2022-04-29       Impact factor: 6.388
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.